Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease "COMPASS"

Active, not recruiting

Phase 3 Results N/A

Summary of Purpose

The primary purpose of this study is to evaluate whether treatment with rivaroxaban and aspirin or rivaroxaban alone is better than aspirin alone in prevention of heart attacks, stroke or cardiovascular death in patients with coronary or peripheral artery disease.

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 25 April 2018.

28 Feb 2013 24 Jan 2013 21 Jul 2017 30 Jun 2021 1 Apr 2018 Unavailable
Start Date First Received 1st Completion Completion Verification Results

Trial Basics

Interventions See All

Conditions

Sponsors

Trial Design

  • Allocation: Randomized
  • Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
  • Purpose: Prevention
  • Endpoint: Safety/Efficacy Study
  • Intervention: Parallel Assignment

Contacts